Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical results in patients with CNS lymphoma. Comparison of predictive value of intraoperative MRI and intraoperative histological examination for diagnostic biopsy yield.

Brain & spine·2024
Same author

Extracorporeal cardiopulmonary resuscitation-based approach to refractory out-of-hospital cardiac arrest: A focus on organ donation, a secondary analysis of a Prague OHCA randomized study.

Resuscitation·2023
Same author

Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.

American journal of hematology·2023
Same author

Hydrops fetalis and failure of hematopoietic stem cell transplantation - A long route to the diagnosis of SPTA1-associated hereditary spherocytosis.

Blood cells, molecules & diseases·2022
Same author

Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).

Annals of hematology·2022
Same author

Targeted therapy of non-small cell lung cancer.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2021

Related Experiment Video

Updated: Dec 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.

P Vockova1, M Svaton2, J Karolova1,3

  • 1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Folia Biologica
|June 9, 2020
PubMed
Summary

Daratumumab shows promise in treating CD20-negative diffuse large B-cell lymphoma (DLBCL) relapses. This anti-CD38 antibody suppressed tumor growth in a preclinical model, suggesting a new therapeutic avenue for patients resistant to rituximab.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.7K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

Related Experiment Videos

Last Updated: Dec 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.7K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma with poor prognosis upon relapse after rituximab-based chemotherapy.
  • CD20-negative DLBCL limits the efficacy of rituximab in relapsed or refractory cases.
  • CD38 is a surface antigen implicated in cell signaling, with its expression varying in DLBCL.

Purpose of the Study:

  • To investigate the efficacy of the anti-CD38 monoclonal antibody daratumumab in a CD20-negative, CD38-positive DLBCL patient-derived xenograft (PDX) model.
  • To explore daratumumab as a potential therapeutic option for relapsed DLBCL, particularly in CD20-negative cases.

Main Methods:

  • Utilized a patient-derived xenograft (PDX) model of CD20-negative, CD38-positive DLBCL.
  • Administered daratumumab in vivo and compared its efficacy against rituximab in suppressing tumor growth.
  • Analyzed tumor samples for changes in CD38 expression following daratumumab treatment.

Main Results:

  • Daratumumab significantly suppressed the growth of subcutaneous PDX tumors more effectively than rituximab.
  • Treatment with daratumumab led to down-regulation of surface CD38 on lymphoma cells, indicating complex internalization.
  • CD38 expression on DLBCL cells, though variable, can be readily assessed.

Conclusions:

  • Daratumumab demonstrates potential as a salvage therapy, possibly in combination with chemotherapy, for CD20-negative relapsed DLBCL.
  • Daratumumab's ability to down-regulate CD38 suggests its utility in targeting DLBCL cells.
  • Daratumumab may also serve as a component for antibody-drug conjugates for targeted DLBCL treatment.